A maximal decrease in cell number of ~ 50% was observed with treatment doses of 2-DG greater than 1 mM in stem cell-like CD133/PROM1HIGH patient-derived GBM cells (1 mM: p < 0.01; 2 mM: p < 0.01; 3 mM: p < 0.01; Fig. 3a). This evidence concerns the gene PROM1 and glioblastoma.